PDG20 COST-EFFECTIVENESS ANALYSIS OF EZETIMIBE AS THE ADD-ON TREATMENT TO MODERATE-DOSE ROSUVASTATIN VERSUS HIGH-DOSE ROSUVASTATIN IN THE SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES IN CHINA: A MARKOV MODEL ANALYSIS BASED ON NSTE-ACS
May 1, 2019, 00:00
10.1016/j.jval.2019.04.699
https://www.valueinhealthjournal.com/article/S1098-3015(19)30891-5/fulltext
Title :
PDG20 COST-EFFECTIVENESS ANALYSIS OF EZETIMIBE AS THE ADD-ON TREATMENT TO MODERATE-DOSE ROSUVASTATIN VERSUS HIGH-DOSE ROSUVASTATIN IN THE SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES IN CHINA: A MARKOV MODEL ANALYSIS BASED ON NSTE-ACS
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)30891-5&doi=10.1016/j.jval.2019.04.699
First page :
Section Title :
Open access? :
No
Section Order :
10302